Citius Oncology, Inc. Market Cap ($58.17 Million)
Market Cap & Net Worth: Citius Oncology, Inc. (CTOR)
Citius Oncology, Inc. market cap. Citius Oncology, Inc. (NASDAQ:CTOR) has a market capitalization of $58.17 Million ($58.17 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21105 globally and #4765 in its home market, demonstrating a -7.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Citius Oncology, Inc.'s stock price $0.55 by its total outstanding shares 105758982 (105.76 Million). Also see Citius Oncology, Inc. (CTOR) cash flow conversion for how efficiently the company converts equity into cash flow.
Citius Oncology, Inc. Market Cap History (2024–2026)
Citius Oncology, Inc. market cap history from 2024 to 2026. Data shows change from $121.62 Million to $58.17 Million (-85.49% CAGR). Check CTOR stock price for real-time trading data and today's change.
Index Memberships
Citius Oncology, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #600 of 976 |
Weight: Citius Oncology, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Citius Oncology, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Citius Oncology, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Citius Oncology, Inc. to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CTOR by Market Capitalization
Companies near Citius Oncology, Inc. in the global market cap rankings as of November 4, 2026. Also see how large is Citius Oncology, Inc.'s balance sheet for a full breakdown of the balance sheet.
Key companies related to Citius Oncology, Inc. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Citius Oncology, Inc. (2024–2026)
Market capitalization of Citius Oncology, Inc. from 2024 to today. Between 2024 and today, Citius Oncology, Inc.'s market cap moved from $121.62 Million to $ 58.17 Million, with a yearly change of -85.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $58.17 Million | -45.00% |
| 2025 | $105.76 Million | -13.04% |
| 2024 | $121.62 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Citius Oncology, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $58.17 Million USD |
| MoneyControl | $58.17 Million USD |
| MarketWatch | $58.17 Million USD |
| marketcap.company | $58.17 Million USD |
| Reuters | $58.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary… Read more